The Promising Effects of Lattice Radiotherapy for Large, Fungating, or Ulcerating Breast Cancers: A Prospective Single-center Study.

Autor:	Ferini G; REM Radioterapia srl, Viagrande, Italy; gianluca.ferini@grupposamed.com.; Department of Medicine and Surgery, Kore University of Enna, Enna, Italy., Zagardo V; REM Radioterapia srl, Viagrande, Italy., Viola A; REM Radioterapia srl, Viagrande, Italy., Patanè D; Department of Nursing Service, Garibaldi Hospital, Catania, Italy., Parisi S; Radiation Oncology Unit, Department of Biomedical, Dental and Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy., Cuccia F; Radiation Oncology, ARNAS Civico Hospital, Palermo, Italy., Piras A; Radioterapia Oncologica, Villa Santa Teresa, Palermo, Italy., Fontana P; Breast Unit, The Mediterranean Institute of Oncology, Viagrande, Italy., Maugeri G; Breast Unit, The Mediterranean Institute of Oncology, Viagrande, Italy., Prestifilippo A; Breast Unit, The Mediterranean Institute of Oncology, Viagrande, Italy., Boncoraglio A; Radiology Unit, Giovanni Paolo II Hospital, Ragusa, Italy., Pontoriero A; Radiation Oncology Unit, Department of Biomedical, Dental and Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy., Harikar M; Clinical Trials Programme, The University of Edinburgh, Edinburgh, U.K., Pergolizzi S; Radiation Oncology Unit, Department of Biomedical, Dental and Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy.
Jazyk:	angličtina
Zdroj:	In vivo (Athens, Greece) [In Vivo] 2024 Sep-Oct; Vol. 38 (5), pp. 2484-2493.
DOI:	10.21873/invivo.13719
Abstrakt:	Background/aim: To evaluate the safety and efficacy of lattice radiotherapy (LRT) for large, inoperable breast cancers. Patients and Methods: In this prospective study, patients who underwent LRT for breast tumors that were ulcerating/fungating/extensively eroding the chest wall, and were ineligible/unwilling for surgery, were enrolled from May 2021 to Nov 2023. Baseline Eastern Cooperative Oncology Group (ECOG) status, pre- and post-LRT numerical rating scale (NRS), and post-LRT changes in quality of life (QoL) were recorded. Survival outcomes were reported at 6 months and 1-year. Median rates of survival and dosimetric parameters were calculated. Kaplan-Meier curves for overall survival (OS), cancer-specific survival (CSS), and failure of local control (LC) were constructed. Results: Ten patients (8 females) underwent LRT. The median age was 76 years (range=57-99 years) and the median ECOG performance status was 2.5 (range=1-4). The planned schedule was completed by 9/10 patients, accounting for a 90% compliance rate. Among patients with pain (n=7), NRS rapidly reduced from 7 (range=5-10) to 3 (range=1-6). The median equivalent uniform dose was 0.71 Gy (0.09-1.59 Gy). The actuarial rates of 6-month LC, CSS, and OS were 75%, 89%, and 61%, respectively, with only LC rate changing to 50% at 1 year. Two patients had local relapse at the six-month and 1-year follow-up, respectively, after having achieved a complete response at three months, and two others died of COVID-19 infection and ischemic stroke. Conclusion: LRT was found to be effective and safe in palliating symptoms among patients with large inoperable breast tumors. (Copyright © 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu